BLFS (BioLife Solutions) Short-term investments

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BLFS BioLife Solutions Inc BLFS
72 GF Score
Price $28.29
GF Value $28.82
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is BioLife Solutions Short-term investments?

Short-term investments only applies to insurance companies.

BLFS
72GF Score
BioLife Solutions Inc BLFS
Short-term investments is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is BioLife Solutions (BLFS) Overvalued in 2026?

Based on GuruFocus' analysis, BioLife Solutions stock appears to be undervalued. The current stock price of $28.29 is trading 1.8% below its estimated GF Value™ of $28.82. GuruFocus considers BioLife Solutions to be Fairly Valued.

Key valuation signals for BLFS:

  • Short-term investments:
  • GF Value™: $28.82 vs. price of $28.29 (1.8% below fair value)
  • GF Score™: 72/100 with 5 warning signs

No single metric tells the full story. See the BLFS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


BioLife Solutions Business Description

Other Exchanges BJX1:Germany
Address 3303 Monte Villa Parkway, Suite 310, Bothell, WA, USA, 98021
BioLife Solutions Inc is a life sciences company that develops, manufactures, and markets bioproduction products and services that are designed to improve quality and de-risk biologic manufacturing, distribution, and transportation in the cell and gene therapy ("CGT") industry. The company provides solutions such as Cell Processing, Cold Chain, and Thawing. The company generates the majority of its revenue from Cell Processing through the biopreservation product "CryoStor". Geographically the company generates the majority of its revenue from the United States.
72GF Score

Get the complete analysis for BLFS

Short-term investments is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$28.29
Price
$28.82
GF Value